NextVein Announces Affordable, High-Performance, Handheld Vein Visualization System

NextVein LLC company today announced a breakthrough product that makes vein visualization affordable for every clinician. The NextVein system is designed from the ground up to be a simple to use, cost-effective solution for successful venous access and vein avoidance.

This augmented reality system uses advanced camera and multicolor projection technology to project the vein pattern on the patient’s skin, providing the clinician a roadmap to the patient’s unique vasculature. The LED projection system overcomes clinician and patient concerns about lasers.

Studies have shown that vein visualization improves important venous access metrics, including:

  • Improved first-time stick success rate,
  • Reduction in patient pain,
  • Fewer escalations,
  • Cost reduction.

NextVein is the first meaningful alternative to expensive vein visualization systems. It offers the core features expected from hand-held vein visualization and adds advanced features like multicolor projection. As a hand-held device, the clinician can quickly assess the patient to identify veins. It converts to hands-free with the NextVein wheeled stand, freeing both hands for the procedure. This state-of-the-art stand provides a reliable, long-reach solution for procedures and doubles as storage while re-charging.

Vein visualization is used:

  • To start IVs by nurses in hospitals and outpatient settings
  • To draw blood by phlebotomists
  • By Dentists, Dental Surgeons, and Dental Anesthesiologists for IV sedation
  • For IV contrast in Imaging Centers
  • For Aesthetic Injectables to avoid veins and visible bruising

NextVein is partnering with Medtech/Medcare (MTMC), the recognized leader in national sales solutions. Jack Moran, MTMC’s managing partner, said, “Our 125 sales executives are trusted partners to providers across the healthcare spectrum. We’re excited to bring this new high-performance, hand-held vein visualization system to our customers. Excellent product at an affordable price is the right combination and will enable our customers to deliver a higher level of care and achieve a higher level of success.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version